Valentine Jehl

2.1k citations

23 papers · 1.1k indexed · 1 hit paper · h-index 11

Neurology top 2%
- Peripheral Neuropathies and Disorders 2
Oncology top 5%
- Lung Cancer Research Studies 9
Epidemiology top 5%
- Neuroendocrine Tumor Research Advances 5
Pathology and Forensic Medicine
- Multiple Sclerosis Research Studies 4
Genetics
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 5
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 4
Statistics and Probability
- Statistical Methods in Clinical Trials 3
Economics and Econometrics
- Health Systems, Economic Evaluations, Quality of Life 2

Co-authors: James C. Yao Judith Klimovsky Marc Peeters Éric Baudin John D. Hainsworth Marianne Pavel Robert Winkler David Lebwohl
Cited by: Neurology Oncology Epidemiology
Partner nations: Switzerland United States Germany

In The Last Decade

Valentine Jehl

23 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Peers

Countries citing papers authored by Valentine Jehl

Since Specialization

Citations

This map shows the geographic impact of Valentine Jehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valentine Jehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valentine Jehl more than expected).

Fields of papers citing papers by Valentine Jehl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valentine Jehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valentine Jehl. The network helps show where Valentine Jehl may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Valentine Jehl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Valentine Jehl Line = papers co-authored together Valentine Jehl links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis Stephen L. Hauser,Jeffrey A. Cohen,J. de Sèze,Sven G. Meuth,Paul S. Giacomini,Jin Nakahara,Celia Oreja‐Guevara,Derrick Robertson,Sibyl Wray,Alit Bhatt,Xixi Hu,Jing Xi,Rebecca Piccolo,Valentine Jehl,Roseanne Sullivan,Ibolya Boer,Heinz Wiendl,Ludwig Kappos	2025	2
2	Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting Dilraj S. Grewal,Charles C. Wykoff,Divya D’Souza,Valentine Jehl,Iulian Alecu,Glenn J. Jaffe	2023	2
3	Pregnancy Outcomes in Patients With MS Following Exposure to Ofatumumab: Updated Results From the Novartis Safety Database (P9-3.014) Riley Bove,Maria Pia Amato,Ruth Dobson,Kristen M. Krysko,Sharon Kay Stoll,Sandra Vukusic,Bassem Yamout,Ronald Zielman,Swetha Krishna Gummuluri,Valentine Jehl,Ulf Schulze Topphoff,Roseanne Sullivan,Simone Fantaccini,Kerstin Hellwig	2023	2
4	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years Stephen L. Hauser,Anne H. Cross,Kevin Winthrop,Heinz Wiendl,Jacqueline Nicholas,Sven G. Meuth,Paul S. Giacomini,Francesco Saccà,Linda Mancione,Ronald Zielman,Morten Bagger,Ayan Das Gupta,Dieter A. Häring,Valentine Jehl,Bernd C. Kieseier,Ratnakar Pingili,Dee Stoneman,Wendy Su,Roman Willi,Ludwig Kappos	2022	45
5	Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study Kaspar Rufibach,Regina Stegherr,Claudia Schmoor,Valentine Jehl,Arthur Allignol,Annette Boeckenhoff,Cornelia Dunger‐Baldauf,Lewin Eisele,Thomas Künzel,Katrin Kupas,Friedhelm Leverkus,Matthias Trampisch,Yumin Zhao,Tim Friede,Jan Beyersmann,(unknown)	2022	2
6	Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis (RMS) Patients from the Phase 3 ASCLEPIOS I and II Trials (1300) Amit Bar‐Or,J. de Sèze,Jorge Correale,Anne Cross,Ludwig Kappos,Krzysztof Selmaj,Heinz Wiendl,Cécile Kerloëguen,Ratnakar Pingili,Roseanne Sullivan,Ayan Das Gupta,Valentine Jehl,Dieter Haering,Martin Merschhemke,Stephen L. Hauser	2021	9
7	Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks Regina Stegherr,Claudia Schmoor,Jan Beyersmann,Kaspar Rufibach,Valentine Jehl,Andreas Brückner,Lewin Eisele,Thomas Künzel,Katrin Kupas,Frank Langer,Friedhelm Leverkus,Anja H. Loos,Christiane Norenberg,Florian Voß,Tim Friede	2021	13
8	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. Reinhard Dummer,Dirk Schadendorf,Paolo A. Ascierto,Ana Arance,Caroline Dutriaux,Michele Maio,Piotr Rutkowski,Michele Del Vecchio,Ralf Gutzmer,Mario Mandalà,L. Thomas,Ernesto Wasserman,James Ford,Marine Weill,L. Andres Sirulnik,Valentine Jehl,Viviana Bozón,Georgina V. Long,Keith T. Flaherty	2016	24
9	Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer Wilfried Eberhardt,Paul Mitchell,Joan H. Schiller,Michael P. Brown,Michael Thomas,Glenn Mills,Valentine Jehl,Shweta Urva,Jeffrey J. De Leo,Sven Gogov,Vassiliki A. Papadimitrakopoulou	2013	4
10	Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer Benjamin Besse,Natasha B. Leighl,Jaafar Bennouna,Vassiliki A. Papadimitrakopoulou,Normand Blais,Anne M. Traynor,Jean‐Charles Soria,Sven Gogov,Neil Miller,Valentine Jehl,Bruce E. Johnson	2013	53
11	Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience James C. Yao,Alexandria T. Phan,Valentine Jehl,Gaurav Shah,Funda Meric‐Bernstam	2013	68
12	Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer Vassiliki A. Papadimitrakopoulou,Jean‐Charles Soria,Annette Jappe,Valentine Jehl,Judith Klimovsky,Bruce E. Johnson	2012	28
13	Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. James C. Yao,Stefano Ricci,Robert Winkler,Valentine Jehl,Marianne Pavel	2011	5
14	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studybreakdown → Marianne Pavel,John D. Hainsworth,Éric Baudin,Marc Peeters,Dieter Hörsch,Robert Winkler,Judith Klimovsky,David Lebwohl,Valentine Jehl,Edward M. Wolin,Kjell Öberg,Eric Van Cutsem,James C. Yao	2011	767
15	Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2). James C. Yao,John D. Hainsworth,Éric Baudin,Marc Peeters,Dieter Hoersch,Lowell Anthony,Judith Klimovsky,K. Grouss,Valentine Jehl,Marianne Pavel	2011	18
16	Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. Lowell Anthony,Marc Peeters,John D. Hainsworth,Éric Baudin,Dieter Hoersch,Judith Klimovsky,K. Grouss,Valentine Jehl,Marianne Pavel,James C. Yao	2011	4
17	Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). N. B. Leighl,Jean‐Charles Soria,Jaafar Bennouna,Normand Blais,Anne M. Traynor,V. Papadimitrakopoulou,Judith Klimovsky,Annette Jappe,Valentine Jehl,B. E. Johnson	2010	15
18	9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) J.C. Soria,Jaafar Bennouna,Natasha B. Leighl,Fadlo R. Khuri,Anne M. Traynor,B. E. Johnson,Allison H. Kay,Normand Blais,Valentine Jehl,V. Papadimitrakopoulou	2009	2
19	Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial Antonio Piga,Kamila Kébaïli,Renzo Galanello,Valentine Jehl,Corinne Rebischung,Henry Maseruka,Lisa Rojkjaer,Gian Luca Forni	2008	8
20	Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study Pascal Piedbois,D. Serin,Franck Priou,P. Laplaige,S. Greget,Élisabeth Angellier,É. Teissier,Jean François Berdah,Michel Fabbro,B. Valenza,Patrice Herait,Valentine Jehl,Marc Buyse	2006	30

About Valentine Jehl

Valentine Jehl is a scholar working on Oncology, Statistics and Probability and Pathology and Forensic Medicine, having authored 23 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (9 papers), Neuroendocrine Tumor Research Advances (5 papers), Lung Cancer Treatments and Mutations (5 papers), Multiple Sclerosis Research Studies (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Statistical Methods in Clinical Trials (3 papers), Peripheral Neuropathies and Disorders (2 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). The work is most often cited by research in Neurology (536 citations), Oncology (809 citations) and Epidemiology (740 citations). Valentine Jehl has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include James C. Yao, Judith Klimovsky, Marc Peeters, Éric Baudin, John D. Hainsworth, Marianne Pavel, Robert Winkler, David Lebwohl, Edward M. Wolin and Kjell Öberg.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact